The Lives and Livelihoods Fund is the largest multilateral fund of its kind in the Middle East
An Indian government-backed Covid-19 vaccine showed it was safe and triggered immune responses during an ongoing early-stage trial, the company involved in the study said in a statement on Wednesday.
Also read: India 'likely to emerge' as country with highest Covid-19 tally
Bharat Biotech, the private company developing Covaxin with the government-run Indian Council of Medical Research (ICMR), said: "Covaxin demonstrated acceptable safety profile and high immune response. . . No serious (grade 3-4) adverse events were reported."
Phase II and Phase III clinical trials are underway.
The company earlier this month sought emergency-use authorisation from the Indian drug regulator for its Covid-19 vaccine to help achieve its plan to launch COVAXIN by the second quarter of 2021.
India has the world's second-highest caseload of coronavirus behind the United States, and it is looking to deploy its vast election machinery to deliver 600 million doses of Covid-19 vaccines to the most vulnerable people in the next six to eight months.
The Lives and Livelihoods Fund is the largest multilateral fund of its kind in the Middle East
Stock market opened with modest gain on Wednesday marking third consecutive session in the upward gain
Union warned it could order several days of strike action over a busy May holiday weekend if its demands are not met
Humidity is set to rise during the night and into Thursday morning
Text messages, social media posts, chatroom messages, altered images, and videos are just a few avenues through which cyberbullying can occur
The building in Muhaisnah 4 had suffered structural damage last week and has been sealed off as authorities conduct investigations
Al Ain, which knocked out Cristiano Ronaldo's Al Nassr in the quarterfinals, reached the final for the first time since 2016
Defeat leaves Chelsea still in ninth, three points adrift of the European places